Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)

NCT05607550 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

398

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
EGFR Exon 20 Mutations

Interventions

DRUG: furmonertinib 240 mg oral, daily
DRUG: furmonertinib 160 mg oral, daily
DRUG: platinum-based chemotherapy

Sponsor

ArriVent BioPharma, Inc.

Collaborators

[object Object]